12.07.2020 |
Scientific publications

VMX-C001 is a Bypassing Agent for FXa-inhibiting DOACs and Displays a Favorable Pharmacokinetic and Pharmacodynamic Profile

Reversal of anticoagulation is important for safe usage of oral factor (F)Xa-inhibiting direct oral anticoagulants (FXa-DOACs).

Related items

24.06.2023

Scientific publications

Coagulation assays for assessing direct FXa inhibitor oral anticoagulant reversal effect
Factor Xa direct oral anticoagulants (Fxa-DOACs) require rapid reversal in patients with serious bleeding or prior to urgent surgery.
Read more

09.07.2022

Scientific publications

Preclinical safety and toxicokinetics of VMX-C001 – an intravenous bypassing agent for factor Xa inhibitors
VMX-C001, a modified form of human zymogen factor X, is being developed to stop or prevent bleeding in patients taking…
Read more